Voya Investment Management LLC trimmed its position in shares of bluebird bio Inc (NASDAQ:BLUE) by 86.9% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 25,550 shares of the biotechnology company’s stock after selling 169,797 shares during the quarter. Voya Investment Management LLC’s holdings in bluebird bio were worth $4,010,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Commonwealth Equity Services LLC boosted its position in shares of bluebird bio by 24.7% during the first quarter. Commonwealth Equity Services LLC now owns 1,936 shares of the biotechnology company’s stock worth $330,000 after purchasing an additional 383 shares in the last quarter. CIBC Asset Management Inc lifted its position in bluebird bio by 28.5% in the 2nd quarter. CIBC Asset Management Inc now owns 1,780 shares of the biotechnology company’s stock valued at $279,000 after acquiring an additional 395 shares in the last quarter. Dynamic Technology Lab Private Ltd lifted its position in bluebird bio by 43.2% in the 2nd quarter. Dynamic Technology Lab Private Ltd now owns 2,040 shares of the biotechnology company’s stock valued at $320,000 after acquiring an additional 615 shares in the last quarter. Aperio Group LLC lifted its position in bluebird bio by 9.7% in the 2nd quarter. Aperio Group LLC now owns 7,295 shares of the biotechnology company’s stock valued at $1,145,000 after acquiring an additional 646 shares in the last quarter. Finally, Xact Kapitalforvaltning AB lifted its position in bluebird bio by 12.3% in the 2nd quarter. Xact Kapitalforvaltning AB now owns 7,330 shares of the biotechnology company’s stock valued at $1,150,000 after acquiring an additional 800 shares in the last quarter. 98.45% of the stock is currently owned by institutional investors.

Several equities research analysts recently commented on BLUE shares. Maxim Group reaffirmed a “hold” rating on shares of bluebird bio in a research report on Monday, August 6th. BidaskClub cut shares of bluebird bio from a “hold” rating to a “sell” rating in a research report on Tuesday, September 11th. Goldman Sachs Group cut shares of bluebird bio from a “conviction-buy” rating to a “buy” rating in a research report on Friday, September 21st. Guggenheim started coverage on shares of bluebird bio in a research report on Monday, September 17th. They issued a “neutral” rating on the stock. Finally, ValuEngine cut shares of bluebird bio from a “strong-buy” rating to a “buy” rating in a research report on Monday, September 17th. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating and fifteen have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $212.05.

In other bluebird bio news, insider David Davidson sold 10,000 shares of bluebird bio stock in a transaction on Monday, July 2nd. The shares were sold at an average price of $153.96, for a total value of $1,539,600.00. Following the sale, the insider now directly owns 34,905 shares in the company, valued at approximately $5,373,973.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Alison Cecily Finger sold 259 shares of bluebird bio stock in a transaction on Monday, August 20th. The shares were sold at an average price of $158.07, for a total transaction of $40,940.13. The disclosure for this sale can be found here. Insiders sold a total of 72,685 shares of company stock worth $11,829,905 over the last quarter. Company insiders own 3.00% of the company’s stock.

Shares of BLUE stock opened at $144.95 on Friday. bluebird bio Inc has a 1 year low of $119.90 and a 1 year high of $236.17.

bluebird bio (NASDAQ:BLUE) last issued its quarterly earnings results on Thursday, August 2nd. The biotechnology company reported ($2.91) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.30) by ($0.61). bluebird bio had a negative net margin of 1,281.01% and a negative return on equity of 31.57%. The business had revenue of $7.80 million during the quarter, compared to analyst estimates of $10.68 million. During the same quarter in the previous year, the firm posted ($1.73) earnings per share. The firm’s quarterly revenue was down 53.3% on a year-over-year basis. analysts forecast that bluebird bio Inc will post -10.8 EPS for the current year.

About bluebird bio

bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease.

Featured Story: What is a put option?

Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for bluebird bio Inc (NASDAQ:BLUE).

Institutional Ownership by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.